Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Sinopharm Signs MOU to In-License Cancer Treatment from Provectus

publication date: Aug 18, 2014
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinopharm (China National Pharmaceutical Group) has signed a Memorandum of Understanding with Provectus Biopharma, a US clinical-stage drug company, to in-license China rights for Provectus's lead drug candidate: PV-10, an immunotherapy aimed at cancer. If the two entities reach a final agreement, Provectus will manufacture PV-10 in the US, and Sinopharm A-THINK will distribute the drug in China. Provectus expects the deal to contain upfront, milestone and royalty payments. More details....

Stock Symbol: (NYSE: PVCT)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...